UCB to acquire Candid Therapeutics

 

• Deal builds upon UCB’s position as a leader in immunology innovation and expands capabilities in next‑generation biologics with potential for immune reset
• Candid’s lead asset, cizutamig, a bispecific antibody directed to B-cell maturation antigen (BCMA) on plasma cells and CD3 on T-cells, is currently in multiple phase 1 clinical studies across various autoimmune diseases
• Total transaction value of up to US $2.2 billion consisting of US $2 billion in upfront payments plus up to US $200 million in potential future milestone payments
• https://www.ucb.com/newsroom/press-releases/article/ucb-to-acquire-candid-therapeutics-building-upon-its-existing-immunology-pipeline-with-novel-t-cell-engagers